Current CTU studies Apr 14
STUDIES OPEN TO RECRUITMENT
TRIAL No.
STUDY
DESCRIPTION
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
BMT
ON/2011/3861
PRoT4
(Prophylactic
Transfer of CD4
Lymphocytes)
ON/2012/4116
UK HAPLO
Study
Multicentre
randomised phase II
study to evaluate the
efficacy of prophylactic
transfer of CD4
lymphocytes after Tcell depleted reduced
intensity HLA-identical
sibling transplantation
for indolent nonHodgkin's lymphoma
and CLL
A UK multicentre
phase II study of
haploidentical stem
cell transplantation in
patients with
haematological
Dr S
Robinson
Dr R
Protheroe
Jon Heywood
Research Nurse
x 26741/bleep 2852
Helen Saldanha
Trial Coordinator
x 26740
Jon Heywood
Research Nurse
x 26741/bleep 2852
Helen Saldanha
Trial Coordinator
x 26740
CRUK
(NIHR)
26/10/2012
UCL
(NIHR)
26/06/2013
EORTC
(NIHR)
26/04/2011
CRUK
(NIHR)
15/11/2012
Commercial
02/08/2013
BRAIN
ON/3468
BR14
EORTC
26053/22054
Adjuvant
Location of trial
treatment:
Outpatient oral
chemotherapy and
Radiotherapy
ON/4041
OPARATIC
eCRF
Location of trial
treatment: NBT
surgery & oral
outpatient
chemotherapy.
ON/4315
ACT IV
Phase III trial on
Concurrent and
Adjuvant
Temozolomide
chemotherapy in non1p/19q deleted
anaplastic glioma. The
CATNON Intergroup
trial.
A Cancer Research
UK Phase I trial of
olaparib (AZD2281),
an oral PARP Inhibitor,
in combination with
extended low-dose
oral temozolomide in
patients with relapsed
glioblastoma
An International,
Randomised, DoubleBlind, Controlled Study
of Rindopepimut/GMCSF with Adjuvant
Temozolomide in
Patients with Newly
Diagnosed, Surgically
Resected, EGFRvIIIpositive Glioblastoma
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Dr K Hopkins
Angela Webb
Research Nurse
x 26753/bleep 2195
Matt Baxter
Asst CTU Manager
x 26734
Angela Webb
Research Nurse
x 26753/bleep 2195
Dr K Hopkins
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Matt Baxter
Asst. CTU Manager
x 26735
Angela Webb
Research Nurse
x 26753/bleep 2195
Dr K Hopkins
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Matt Baxter
Asst. CTU Manager
x 26735
STUDIES OPEN TO RECRUITMENT
TRIAL No.
ON/4297
TAVAREC
ON/4382
TAMIGA
STUDY
DESCRIPTION
Randomised trial
assessing the
significance of
Bevacizumab in
recurrent grade II and
Grade III gliomas. The
TAVAREC trial.
A double-blind,
placebo-controlled,
randomized, Phase IIIb
trial evaluating the
efficacy and safety of
standard of care
(SOC) +/-continuous
bevacizumab
treatment following
progression of disease
(PD) in patients with
glioblastoma (GBM)
after first (1st)-line
treatment with
radiotherapy,
temozolomide and
bevacizumab
(MO28347)
P.I.
CONTACT
PORTFOLIO
DATE
OPENED
EORTC
(NIHR)
22/01/2014
Commerical
(NIHR)
31/01/2014
SPONSOR/
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Dr C Herbert
Angela Webb
Research Nurse
x 26753/bleep 2195
Matt Baxter
Asst. CTU Manager
x 26735
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Dr K Hopkins
Angela Webb
Research Nurse
x 26753/bleep 2195
Matt Baxter
Asst. CTU Manager
x 26735
BREAST
ON/3235
MOSS
Location of trial
treatment: LG2
R/T Pre-treatment
The tumour bed as
target for breast
irradiation following
breast conserving
surgery
Dr A Bahl
Dana Weston
Research
Radiographer
x 22433/bleep 2436
24/08/2010
Investigator
led
Sylvia Pearson
Snr Trial Coordinator
ON HOLD
FROM
01-Apr-13
x 26747
ON/3241
IMPORT HIGH
Location of trial
treatment: LG2
Radiotherapy
Randomised trial
testing dose escalated
intensity modulated
radiotherapy in women
with higher than
average local tumour
recurrence risk after
breast conservation
surgery and
appropriate systemic
therapy for early breast
cancer
Dana Weston
Research
Radiographer
x 26754/bleep 2436
Dr A Bahl
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
Helen Saldanha
Trial Coordinator
x 26740
ICR (NIHR)
19/07/2011
STUDIES OPEN TO RECRUITMENT
TRIAL No.
ON/2010/3589
BIG 3-07
(TROG 07.01)
Location of trial
treatment: LG2
Radiotherapy
ON/3810
FAST
FORWARD
Location of trial
treatment: LG2
Radiotherapy
ON/3941
ARISTACAT
Location of trial
treatment: CDU
ON/4082
OPTIMA
Location of trial
treatment: CDU
STUDY
DESCRIPTION
P.I.
Dr A Bahl
Randomised clinical
trial testing a 1-week
course of curative
whole breast
radiotherapy against a
standard 3-week
schedule in terms of
local cancer control
and late adverse
effects in patients with
early breast cancer
Dr A Bahl
Optimal Personalised
Treatment of early
breast cancer using
Multi-parameter
Analysis
SPONSOR/
PORTFOLIO
DATE
OPENED
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
BIG 3-07 (TROG
07.01) A Randomised
Phase III Study of
Radiation Doses and
Fractionation
Schedules for Ductal
Carcinoma in Situ
(DCIS) of the Breast
ARomatase Inhibition
plus/minus
SaracaTinib as
Advanced breast
CAncer Therapy: a
randomised phase II
study of aromatase
inhibition plus/minus
the src-inhibitor
AZD0530 in postmenopausal women
with advanced breast
cancer
CONTACT
Dana Weston
Research
Radiographer
x 26754/bleep 2436
Lothian
Health
Board
(NIHR)
21/11/2011
ICR / NIHR
06/02/2012
Common
Services
Agency
(NIHR)
04/10/2012
UCL (NIHR)
12/03/2013
Helen Saldanha
Trial Coordinator
x 26740
Dana Weston
Research
Radiographer
x 26754/bleep 2436
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
Helen Saldanha
Trial Coordinator
x 26740
Liz Allison
Research Nurse
x 26736/bleep 2999
Dr J
Braybrooke
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Angela Webb
Research Nurse
x 26753/bleep 2195
Robert Hollister
Trial Coordinator
x 26742
Dr J
Braybrooke
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Robert Hollister
Trial Coordinator
x 26742
STUDIES OPEN TO RECRUITMENT
TRIAL No.
ON/4220
KATHERINE /
BO27938 NCRN384
STUDY
DESCRIPTION
A Randomised,
Multicentre, OpenLabel Phase III Study
to Evaluate the
Efficacy and Safety of
Trastuzumab
Emtansine Versus
Trastuzumab as
Adjuvant Therapy for
Patients With Her2Positive Primary
Breast Cancer who
have Residual Tumour
present pathologically
in the breast or axillary
lyph nodes following
preoperative therapy
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Dr J
Braybrooke
Liz Allison
Research Nurse
x 26736/bleep 2999
Angela Webb
Research Nurse
x 26753/bleep 2195
Commercial
(NIHR)
28/06/2013
Robert Hollister
Trial Coordinator
x 26742
COLORECTAL
ON/1707
NSCCG
{Also open at NBT}
observational –
genetic
epidemiology
National Study of
Colorectal Cancer
Genetics
Dr S Falk
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
ICR
(NIHR)
14/04/2004
Location of trial
treatment: Blood
sample only
ON/2776
FOxTROT
(589)
adjuvant
{Cross-site trial
with NBT}
Liz Allison
Research Nurse
x 26736/bleep 2999
Fluoropyrimidine,
Oxaliplatin & Targeted
Receptor preOperative Therapy for
colon cancer
Mr M
Thomas
Location of trial
treatment: CDU
ON/3529
FOXFIRE
neo-adjuvant
Location of trial
treatment: CDU &
Oxford
Jon Heywood
Research Nurse
x 26741/bleep 2852
Angela Webb
Research Nurse
x 26753/bleep 2195
Uni of
B’ham
08/07/2008
(NIHR)
Paul Armenise
Trial Coordinator
x 26743
An open-label
randomised trial of 5fluorouracil, oxaliplatin
and folinic acid +/interventional radioembolisation as first
line treatment for
patients with
unresectable liver-only
or liver-predominant
metastatic colorectal
cancer
Liz Allison
Research Nurse
x 26736/bleep 2999
Jon Heywood
Research Nurse
x 26741/bleep 2852
Dr S Falk
Angela Webb
Research Nurse
x 26753/bleep 2195
Paul Armenise
Trial Coordinator
x 26743
Uni of
Oxford
(NIHR)
08/08/2011
STUDIES OPEN TO RECRUITMENT
TRIAL No.
STUDY
DESCRIPTION
P.I.
CONTACT
PORTFOLIO
DATE
OPENED
UCL (NIHR)
01/02/2012
Commercial
20/06/2012
Cardiff
University
24/10/2013
SPONSOR/
Liz Allison
Research Nurse
x 26736/bleep 2999
ON/3562
ARISTOTLE
neo-adjuvant
Location of trial
treatment: CDU &
Treatment floor
A phase III trial
comparing standard
versus novel CRT as
pre-operative
treatment for MRI
defined locally
advanced rectal
cancer
Jon Heywood
Research Nurse
x 26741/bleep 2852
Dr S Falk
Angela Webb
Research Nurse
x 26753/bleep 2195
Paul Armenise
Trial Coordinator
x 26743
ON3912
ACORN
Location of trial
treatment:
Observatoinal only
ON/4206
COPERNICUS
Avastin COloRectal
Non-interventional
study- an observational
study of avastin®
(bevacizumab) in
combination with
chemotherapy for
treatment of first line
metastatic colorectal
adenocarcinoma
A Phase II study of
neoadjuvant
chemotherapy given
before short course
preoperative
radiotherapy (SCPRT)
as treatment for
patients with MRIstaged operable rectal
cancer at high risk of
metastatic relapse
Dr S Falk
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
Paul Armenise
Trial Coordinator
x 26743
Liz Allison
Research Nurse
x 26736/bleep 2999
Jon Heywood
Research Nurse
x 26741/bleep 2852
Dr S Falk
Angela Webb
Research Nurse
x 26753/bleep 2195
Paul Armenise
Trial Coordinator
x 26743
Liz Allison
Research Nurse
x 26736/bleep 2999
ON/4378
FOCUS-4
Molecular selection of
therapy in colorectal
cancer: a molecularlystratified randomised
controlled trials
programme
Jon Heywood
Research Nurse
x 26741/bleep 2852
Dr S Falk
Angela Webb
Research Nurse
x 26753/bleep 2195
Paul Armenise
Trial Coordinator
x 26743
MRC
(NIHR)
Opening
imminently
STUDIES OPEN TO RECRUITMENT
TRIAL No.
STUDY
DESCRIPTION
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
GYNAE
ON/3790
ICON 8
Location of trial
treatment: CDU
An international phase
III randomised trial of
dose-fractionated
chemotherapy
compared to standard
three-weekly
chemotherapy,
following immediate
primary surgery or as
part of delayed primary
surgery, for women
with newly diagnosed
epithelial ovarian,
fallopian tube or
primary peritoneal
cancer
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Dr H Booz
Jon Heywood
Research Nurse
x 26741/bleep 2852
MRC
(NIHR)
25/11/2011
Commercial
(NIHR)
01/03/2013
Robert Hollister
Trial Coordinator
x 26742
Seonaid Wright
Research Nurse
x 26755/bleep 2459
ON/3925
DESKTOP III
Location of trial
treatment: CDU
A randomised
multicentre study to
compare the efficacy
of additional tumour
debulking surgery
versus chemotherapy
alone for recurrent
platinum-sensitive
ovarian cancer
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Dr J Murdoch
Jon Heywood
Research Nurse
x 26741/bleep 2852
Robert Hollister
Trial Coordinator
x 26742
ON/4295
OSCAR 1
ON/4176
TRIOC
An observational study
of avastin®
(bevacizumab) as first
line therapy in patients
with advanced ovarian
cancer
A Randomised Parallel
Group Double-Blind
Phase II Study to
Assess the Activity of
Trovax® (MVA-5T4)
Versus Placebo in
Patients with Relapsed
Asymptomatic
Epithelial Ovarian,
Fallopian Tube or
Primary Peritoneal
Cancer
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
Dr A Walther
Robert Hollister
Trial Coordinator
x 26742
Commercial
(NIHR)
02/08/2013
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Dr A Walther
UCL (NIHR)
Jon Heywood
Research Nurse
x 26741/bleep 2852
Robert Hollister
Trial Coordinator
x 26742
Opening
imminently
STUDIES OPEN TO RECRUITMENT
TRIAL No.
ON/2013/4463
BriTROC-1
STUDY
DESCRIPTION
The UK Translational
Research in Ovarian
Cancer Collaborative
Sample collection
study to investigate the
role of Homologous
Recombination
Deficiency in platinum
sensitivity in recurrent
high grade serous
ovarian cancer
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Dr A Walther
Jon Heywood
Research Nurse
x 26741/bleep 2852
NHS
Greater
Glasgow &
Clyde
(NIHR)
Opening
imminently
Robert Hollister
Trial Coordinator
x 26742
HAEMATOLOGY
CH/1799
Leukaemia
Samples
(594)
ALL
sample study
Location of trial
treatment: N/A
blood study
ON/3067
AML 17
1st
line
eCRF
Location of trial
treatment: Ward
62 and Haem Day
Unit
ON/3149
Cytarabine
Sensitivity
sample study
Location of trial
treatment: Sample
study
The use of allogeneic
T-lymphocytes (CTL)
in adults with acute
leukaemia (The use of
cytotoxic t-lymphocytes
(CTCs) as adoptive
immunotherapy in
patients with acute
lymphoblastic
leukaemia after bone
marrow transplant
Working parties on
leukaemia in adults
and children trial in
acute myeloid
leukaemia or high risk
myelodysplastic
syndrome 17
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Dr J Bird
Jon Heywood
Research Nurse
x 26741/bleep 2852
National
Blood
Service
01/03/2008
Lisa Mayne
Trial Coordinator
x 26746
Jon Heywood
Research Nurse
x 26741/bleep 2852
Dr P Mehta
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Cardiff
University
09/07/2009
(NIHR)
Lisa Mayne
Trial Coordinator
x 26746
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Cytarabine Sensitivity
Study - Bacterial
Biosensors for rapid
pre-screening of
chemotherapy efficacy
Dr P Mehta
Jon Heywood
Research Nurse
x 26741/bleep 2852
Lisa Mayne
Trial Coordinator
x 26746
Frimley
Park
Hospital
(NIHR)
18/12/2009
STUDIES OPEN TO RECRUITMENT
TRIAL No.
ON/3418
UKALL 14
1st line
Location of trial
treatment: Ward
62 and Haem Day
Unit
ON/3290
PASS
eCRF
Location of trial
treatment: N/A
ON/3368
MYELOMA XI
1st line
Also recruiting at
NBT
Location of trial
treatment:
Outpatient oral
chemotherapy and
Haem Day Unit
ON/3613
REVEAL
1st line
Location of trial
treatment: Haem
Day Unit
ON/3532
PNH Registry
eCRF
Location of trial
treatment:
Outpatients
STUDY
DESCRIPTION
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
A randomised trial for
adults with newly
diagnosed acute
lymphoblastic
leukaemia
Prof D Marks
Jon Heywood
Research Nurse
x 26741/bleep 2852
UCL
(NIHR)
04/02/2011
Commercial
29/06/2010
CTRU
Leeds
(NIHR)
12/05/2011
UCL
(NIHR)
13/04/2012
Lisa Mayne
Trial Coordinator
x 26746
A non-interventional
observational post
authorisation safety
study of subjects
treated with
lenalidomide
Randomised
comparisons in
myeloma patients of all
ages of thalidomide,
lenalidomide and
bortezomib
combinations, and
maintenance
lenalidomide
Dr J Bird,
x 21120
Dr J Bird
jenny.bird@uhbristol.nhs.uk
Call CTU on
x 26733
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Dr J Bird
Jon Heywood
Research Nurse
x 26741/bleep 2852
Emily Foulstone
Trial Coordinator
x 26738
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
A Pilot Study of
Relapsed or Refractory
Patients Using
Velcade (Bortezomib)
Combination
Chemotherapy in AL
Amyloidosis
Dr J Bird
The Paroxysmal
Nocturnal
Haemoglobinuria
(PNH) Registry (M07001)
Dr P Mehta
Jon Heywood
Research Nurse
x 26741/bleep 2852
Emily Foulstone
Trial Coordinator
x 26738
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
Lisa Mayne
Trial Coordinator
x 26746
Commercial
(NIHR)
23/09/2011
STUDIES OPEN TO RECRUITMENT
TRIAL No.
ON/3722
LI-1
Location of trial
treatment: Ward
62 and Haem Day
Unit
CH/3875
UKALL 2011
Location of trial
treatment: Ward
62 and Haem Day
Unit
PA/2519
MDSBio
Location of trial
treatment: Haem
Day Unit for BM /
Outpatients
STUDY
DESCRIPTION
A Programme of
Development for older
patients with Acute
Myeloid Leukaemia
and High Risk
Myelodysplastic
Syndrome
United Kingdom
National Randomised
Trial For Children and
Young Adults with
Acute Lymphoblastic
Leukaemia and
Lymphoma 2011
Molecular and
functional
characterisation of
bone marrow function
in normal subjects,
myelodysplastic
syndromes (MDS),
acute myeloid
leukaemia (AML) and
secondary disorders of
haematopoiesis
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Dr P Mehta
Jon Heywood
Research Nurse
x 26741/bleep 2852
Cardiff Uni /
NIHR
23/03/2012
Lisa Mayne
Trial Coordinator
x 26746
John
Moppett
(BCH)
Prof D Marks
(BHOC Lead)
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Jon Heywood
Research Nurse
x 26741/bleep 2852
Uni of
Birmingham
06/06/2012
(NIHR)
Lisa Mayne
Trial Coordinator
x 26746
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Dr P Mehta
Jon Heywood
Research Nurse
x 26741/bleep 2852
(NIHR)
25/07/2012
UCL
(NIHR)
12/11/2013
Lisa Mayne
Trial Coordinator
x 26746
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
ON/4143
UKALL 60+
e-CRF
Phase 2 study for older
adults with Acute
Lymphoblastic
Leukaemia
Prof D Marks
Jon Heywood
Research Nurse
x 26741/bleep 2852
Lisa Mayne
Trial Coordinator
x 26746
ON/2014/4522
MUK5
A phase II randomised
trial of carfilzomib,
cyclophosphamide and
dexamethasone (CCD)
vs cyclophosphamide,
velcade and
dexamethasone (CVD)
for first relapse and
primary refractory
multiple myeloma
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Dr J Bird
Jon Heywood
Research Nurse
x 26741/bleep 2852
Emily Foulstone
Trial Coordinator
x 26738
Uni of
Leeds
(NIHR)
Opening
imminently
STUDIES OPEN TO RECRUITMENT
TRIAL No.
ON/4265
AZA-MDS-003
e-CRF
ON/4020
InoVATE
(INOTUZUMA
B)
e-CRF
Location of
trial treatment:
Haem Day
Unit
STUDY
DESCRIPTION
A Phase 3,
Multicentre,
Randomised, DoubleBlind Study To
Compare The Efficacy
And Safety Of Oral
Azacitidine Plus Best
Supportive Care
Versus Placebo Plus
Best Supportive Care
In Subjects With Red
Blood Cell
TransfusionDependent Anemia
And
Thrombocytopenia
Due To IPSS LowerRisk Myelodysplastic
Syndromes
An Open-label,
Randomised Phase 3
Study of Inotuzumab
Ozogamicin Compared
to a Defined
Investigator’s Choice
in Adult Patients with
Relapsed or Refractory
CD22-Positive Acute
Lymphoblastic
Leukemia (ALL)
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Dr P Mehta
Jon Heywood
Research Nurse
x 26741/bleep 2852
Commercial
(NIHR)
17/10/2013
Lisa Mayne
Trial Coordinator
x 26746
Jon Heywood
Research Nurse
x 26741/bleep 2852
Prof D Marks
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Lisa Mayne
Trial Coordinator
x 26746
Commercial
(NIHR)
24/01/13
STUDIES OPEN TO RECRUITMENT
TRIAL No.
STUDY
DESCRIPTION
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
HEAD & NECK
ON/3636
ART DECO
Adjuvant
Location of trial
treatment: LG2
Radiotherapy:
Ward 61
Chemotherapy
ON/3803
IoN
Location of trial
treatment: Ward
61 Isotope
treatment rooms
A Randomised
Multicentre
Accelerated
Radiotherapy Study of
Dose Escalated
Intensity Modulated
Radiotherapy vs
Standard Dose
Intensity Modulated
Radiotherapy in
Patients Receiving
Treatment for Locally
Advanced Laryngeal
and Hypopharyngeal
Cancers (NIHR)
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
Dr M Beasely
Dana Weston
Research
Radiographer
x 26754/bleep 2436
Aintree
University
Hospitals
NHS
Foundation
Trust
(NIHR)
10/01/2011
UCL/NIHR
24/05/2012
University
of Warwick
(NIHR)
26/11/2012
Helen Saldanha
Trial Coordinator
x 26740
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
Is ablative radio-iodine
Necessary for low risk
differentiated thyroid
cancer patients
Dr M Beasley
Dana Weston
Research
Radiographer
x 26754/bleep 2436
Helen Saldanha
Trial Coordinator
x 26740
ON/3957
DeESCALATE
Location of trial
treatment: Ward
61
De-ESCALaTE HPV Determination of
Epidermal growth
factor receptor-inhibitor
(cetuximab) versus
Standard
Chemotherapy
(cisplatin) early And
Late Toxicity Events in
Human
Papillomavirus-positive
oropharyngeal
squamous cell
carcinoma
Stephen Lang
Research Nurse
x 26745/bleep 6225
Angela Webb
Research Nurse
x 26753/bleep 2195
Dr H Booz
Dana Weston
Research
Radiographer
x 26754/bleep 2436
Emily Foulstone
Trial Coordinator
x 26738
STUDIES OPEN TO RECRUITMENT
TRIAL No.
STUDY
DESCRIPTION
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
Stephen Lang
Research Nurse
x 26745/bleep 6225
ON/3552
HOPON
Location of trial
treatment:
Hyperbaric oxygen
treatment to be
administered
either in Cariff or
Plymouth
hospitals
HOPON (Hyperbaric
Oxygen for the
Prevention of
Osteoradionecrosis): A
Randomised
Controlled Trial of
Hyperbaric Oxygen to
prevent
Osteoradionecrosis of
the Irradiated Mandible
Angela Webb
Research Nurse
x 26753/bleep 2195
Dr M Beasley
Dana Weston
Research
Radiographer
x 26754/bleep 2436
Uni of
Liverpool /
Aintree Uni
(NIHR)
30/11/2012
MRC
(NIHR)
12/02/2007
Emily Foulstone
Trial Coordinator
x 26738
LUNG
ON/2490
QUARTZ
(522)
Metastatic
Location of trial
treatment: LG2
radiotherapy.
ON/3848
SMART
Location of trial
treatment: LG2
Radiotherapy
A phase 111 multicentre randomised
controlled trial to
assess whether
optimal supportive
care alone (including
Dexamethasone) is as
effective as optimal
supportive care
(including
Dexamethasone) plus
whole brain
radiotherapy in the
treatment of patients
with inoperable brain
metastases from non
small cell lung cancer.
Surgical and large
bore pleural
procedures in
malignant pleural
Mesothelioma And
Radiotherapy Trial
(SMART trial) - RCT
evaluating whether
prophylactic
radiotherapy reduces
the incidence of
procedure tract
metastases
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
Dr C Comins
Dana Weston
Research
Radiographer
x 26754/bleep 2436
Helen Saldanha
Trial Coordinator
x 26740
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
Dr C Comins
Dana Weston
Research
Radiographer
x 26754/bleep 2436
Helen Saldanha
Trial Coordinator
x 26740
NBT / NIHR
03/01/12
STUDIES OPEN TO RECRUITMENT
TRIAL No.
STUDY
DESCRIPTION
ON/4267
LungART
Phase III study
comparing postoperative conformal
radiotherapy to no
post-operative
radiotherapy in
patients with
completely resected
non-small cell lung
cancer and mediastinal
N2 Involvement
P.I.
CONTACT
PORTFOLIO
DATE
OPENED
NIHR
28/10/2013
Commercial
17/09/2013
Leeds
Teaching
Hospital
(NIHR)
13/01/2009
NIHR
23/05/2013
SPONSOR/
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
Dr C Comins
Dana Weston
Research
Radiographer
x 26754/bleep 2436
Helen Saldanha
Trial Coordinator
x 26740
LYMPHOMA
ON/4195
ZEST
A Phase 3, Openlabel, Multicentre,
Randomised Study of
Sequential Zevalin
(ibritumomab tiuxetan)
versus Observation in
Patients at Least 60
Years of Age with
Newly Diagnosed
Diffuse Large B-cell
Lymphoma in PETnegative Complete
Remission After RCHOP or R-CHOP-like
Therapy
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
Dr M Beasley
Dana Weston
Research
Radiographer
x 26754/bleep 2436
Helen Saldanha
Trial Coordinator
x 26740
MELANOMA/SKIN
ON/2815
Melanoma
Lifestyle
Study
The melanoma lifestyle
study
Dr D de
Berker
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
Location of trial
treatment: N/A
sample study
ON/4205
IMAGE
A multi-national,
prospective,
observational study in
patients with
unresectable or
metastatic melanoma,
using Yervoy
(ipilimumab)
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
Dr C Herbert
Paul Armenise
Trial Coordinator
x 26743
STUDIES OPEN TO RECRUITMENT
TRIAL No.
STUDY
DESCRIPTION
ON/4242
BRIM8 –
GO27826
A phase III,
randomized, doubleblind, placebo
controlled study of
vemurafenib
(RO5185426) adjuvant
therapy in patients with
surgically resected,
cutaneous BRAFmutant melanoma at
high risk for recurrence
ON/4291
ZeSS
A Prospective
Observational Safety
Study of Patients with
BRAFV600 Mutationpositive Unresectable
or Metastatic
Melanoma Treated
with Vemurafenib
(Zelboraf®)
ON/2013/4344
NEMO
A randomized Phase
III, open label,
multicenter, two-arm
study comparing the
efficacy of MEK162
versus Dacarbazine in
patients with advanced
unresectable or
metastatic NRAS
mutation positive
melanoma
P.I.
CONTACT
PORTFOLIO
DATE
OPENED
Commercial
29/07/2013
Commercial
05/07/2013
SPONSOR/
Stephen Lang
Research Nurse
x 26745/bleep 6225
Dr C Herbert
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Paul Armenise
Trial Coordinator
x 26743
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
Dr C Herbert
Paul Armenise
Trial Coordinator
x 26743
Stephen Lang
Research Nurse
x 26745/bleep 6225
Dr C Herbert
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
18/03/2014
Commercial
Paul Armenise
Trial Coordinator
x 26743
PALLIATIVE
Dana Weston
Research
Radiographer
x 26754/bleep 2436
A Randomised phase
III trial of single fraction
radiotherapy compared
to multifraction
radiotherapy in
patients with
metastatic spinal cord
compression
Dr K Hopkins
SU/2013/4332
TREC
Transanal Endoscopic
Microsurgery (TEM)
and Radiotherapy in
Early Rectal Cancer
Mr M
Thomas
Rebecca Houlihan
Surgical Research
Nurse, BRI
x 24551/bleep 6304
ON/2013/4264
ROCS
Radiotherapy after
Oesophageal Cancer
Stenting Study
Prof J
Blazeby
Katrina Hurley
Snr Research Nurse
Surgical Research
Team x 204532
ON/3347
SCORAD III
Metastatic
Location of trial
treatment: LG2
Radiotherapy
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
UCL
(NIHR)
15/07/2010
Helen Saldanha
Trial Coordinator
x 26740
Uni of
Birmingham
26/09/2013
(NIHR)
Velindre
NHS Trust
(NIHR)
In set-up
STUDIES OPEN TO RECRUITMENT
TRIAL No.
STUDY
DESCRIPTION
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
SARCOMA
ON/3590
Axi STS
2nd & 3rd line
Location of trial
treatment: Home
ON/3696
CASPS
Metastatic
Location of trial
treatment: Home
ON/3947
STRASS
Location of trial
treatment: LG2
Radiotherapy
A clinicopathological
phase II study of
axitinib in patients with
advanced
angiosarcoma and
other soft tissue
sarcomas
Stephen Lang
Research Nurse
x 26745/bleep 6225
Dr A
Dangoor
Liz Allison
Research Nurse
x 26736/bleep 2999
Robert Hollister
Trial Coordinator
x 26742
Sheffield
teaching
hospitals
NHS
Foundation
Trust
(NIHR)
09/05/2011
ICR/Royal
Marsden
(NIHR)
26/09/2011
EORTC
(NIHR)
12/11/2012
Stephen Lang
Research Nurse
x 26745/bleep 6225
A phase II trial of
Cediranib in the
treatment of patients
with alveolar soft part
sarcoma
Dr A
Dangoor
Liz Allison
Research Nurse
x 26736/bleep 2999
Robert Hollister
Trial Coordinator
x 26742
A phase III randomised
study of preoperative
radiotherapy plus
surgery versus surgery
alone for patients with
Retroperitoneal
sarcoma (RPS)
Dana Weston
Research
Radiographer
x 26754/bleep 2436
Dr P Cornes
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
Helen Saldanha
Trial Coordinator
x 26740
CH/3909
VIT 09-10
International
randomised phase II
trial of the combination
of vincristine and
irinotecan with or
withour temozolomide
(VI or VIT) in children
and adults with
refractory or relapsed
rhabdomyosarcoma
Stephen Lang
Research Nurse
x 26745/bleep 6225
Dr H Rees
TEENAGERS & YOUNG ADULTS
Liz Allison
Research Nurse
x 26736/bleep 2999
Robert Hollister
Trial Coordinator
x 26742
Commercial
(NIHR)
19/08/2013
(BHOC)
STUDIES OPEN TO RECRUITMENT
TRIAL No.
ON/4044
BRIGHTLIGHT
Location of trial
treatment: N/A
non-chemo trial
STUDY
DESCRIPTION
The 2012 TYA Cancer
Cohort Study (the
BRIGHTLIGHT Study).
Do specialist cancer
services for teenagers
and young adults
(TYA) add value?
P.I.
Dr A
Cameron
CONTACT
Vicki Kitchker
Research Nurse
x 26744/bleep 3279
Sylvia Pearson
SPONSOR/
PORTFOLIO
DATE
OPENED
UCL
(NIHR)
12/11/2012
ICR
(NIHR)
23/04/2007
MRC
(NIHR)
06/08/2008
ICR (NIHR)
15/10/2010
Uni of
Warwick
(NIHR)
31/10/2013
Snr Trial Coordinator
x 26747
TESTICULAR
ON/2537
Testicular
Genetics
Location of trial
treatment:
Genetics trial so
no treatment given
ON/2826
TRISST
(TE24)
(585)
Imaging
Identification of
testicular germ cell
tumour susceptibility
genes- the UK
Genetics of testicular
genetics study
Dr J
Braybrooke
Liz Allison
Research Nurse
x 26736/bleep 2999
Trial Of Imaging and
Schedule in Seminoma
Testes
Dr J
Braybrooke
Location of trial
treatment:
Imaging trial so no
treatment given
ON/3452
111 TRIAL
Adjuvant
Location of trial
treatment: Days 13 treatment given
on Ward 61; Days
8 & 15 treatment
given on CDU
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
A single group trial
evaluating one cycle of
adjuvant BEP
chemotherapy in high
risk, stage 1 nonseminomatous germ
cell tumours of the
testis (NSGCTT)
Angela Webb
Research Nurse
x 26753/bleep 2195
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
Liz Allison
Research Nurse
x 26736/bleep 2999
Dr J
Braybrooke
Angela Webb
Research Nurse
x 26753/bleep 2195
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
UNSPECIFIED
ON/4310
SELECT-D
e-CRF
Anticoagulation
Therapy in SELECTeD
Cancer Patients at
Risk of Recurrence of
Venous
Thromboembolism
Stephen Lang
Research Nurse
x 26745/bleep 6225
Dr A Kuchel
Angela Webb
Research Nurse
x 26753/bleep 2195
Lisa Mayne
Trial Coordinator
x 26746
STUDIES OPEN TO RECRUITMENT
TRIAL No.
STUDY
DESCRIPTION
P.I.
CONTACT
PORTFOLIO
DATE
OPENED
Southampton
Uni
26/05/2007
SPONSOR/
UPPER GI
Angela Webb
Research Nurse
x 26753/bleep 2195
ON/2513
BILCAP
(533)
Adjuvant
Location of trial
treatment: Oral
chemotherapy
dispensed
A randomised clinical
trial evaluating
adjuvant
chemotherapy with
capecitabine
compared to expectant
treatment alone
following surgery for
biliary tract cancer
Sharon Short
Research Nurse
x 26751/bleep 3463
Dr S Falk
Seonaid Wright
Research Nurse
x 26755/bleep 2459
(NIHR)
Emily Foulstone
Trial Coordinator
x 26738
Sharon Short
Research Nurse
x 26751/bleep 3463
ON/2646
ST03
(553)
neo adjuvant
Location of trial
treatment: Ward
61
A randomised phase
II/III trial of
perioperative
chemotherapy with or
without bevacizumab
in operable
adenocarcinoma of the
stomach and GO
junction
Angela Webb
Research Nurse
x 26753/bleep 2195
Dr S Falk
Seonaid Wright
Research Nurse
x 26755/bleep 2459
MRC
(NIHR)
27/08/2008
Emily Foulstone
Trial Coordinator
x 26738
Sharon Short
Research Nurse
x 26751/bleep 3463
ON/2844
ESPAC-4
Adjuvant
Location of trial
treatment: CDU
Combination versus
single agent
chemotherapy in
resectable pancreatic
cancer. European
Study Group for
PAncreatic Cancer
Trial 4
Angela Webb
Research Nurse
x 26753/bleep 2195
Dr S Falk
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Emily Foulstone
Trial Coordinator
x 26738
Uni of
Liverpool
(NIHR)
09/04/2009
STUDIES OPEN TO RECRUITMENT
TRIAL No.
ON/4097
MetMAb
Location of trial
treatment: CDU
ON/3953
GATSBY
NCRN369
Location of trial
treatment: 1st
treatment of TDm-1
administered on
Ward 61;
subsequently
administered on
CDU
ON/4212
ChOPIN
ON/4241
RESORCE
Location of trial
treatment: Oral
treatment
dispensed
STUDY
DESCRIPTION
A Randomised, Phase
III, Multicentre,
Double-Blind, PlaceboControlled Study
Evaluating the Efficacy
and Safety of
Onartuzumab
(Metmab) In
Combination With 5Fluorouracil, Folinic
Acid, And Oxaliplatin
(Mfolfox6) In Patients
With Metastatic Her2Negative Met-Positive
GO Cancer
A Randomised,
Multicentre, Adaptive
Phase II/III Study To
Evaluate The Efficacy
And Safety Of
Trastuzumab
Emtansine (T-Dm1)
Versus Taxane
(Docetaxel Or
Paclitaxel) In Patients
With Previously
Treated Locally
Advanced Or
Metastatic Her2Positive Gastric
Cancer, Including
Adenocarcinoma Of
The GO Junction
Chemoprevention Of
Premalignant Intestinal
Neoplasia (ChOPIN)
incorporating Inherited
Predisposition of
Oesophageal
Diseases (IPOD)
A randomised, double
blind, placebocontrolled, multicenter
phase III study of
regorafenib in patients
with hepatocellular
carcinoma (HCC) after
sorafenib
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
Sharon Short
Research Nurse
x 26751/bleep 3463
Angela Webb
Research Nurse
x 26753/bleep 2195
Dr S J Falk
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Commercial
(NIHR)
28/01/2013
Emily Foulstone
Trial Coordinator
x 26738
Angela Webb
Research Nurse
x 26753/bleep 2195
Sharon Short
Research Nurse
x 26751/bleep 3463
Dr S J Falk
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Commercial
(NIHR)
11/12/2012
Emily Foulstone
Trial Coordinator
x 26738
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
Dr S J Falk
Emily Foulstone
Trial Coordinator
x 26738
Angela Webb
Research Nurse
x 26753/bleep 2195
QMUL
(NIHR)
09/05/2013
Commercial
17/07/2013
Sharon Short
Research Nurse
x 26751/bleep 3463
Dr S J Falk
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Emily Foulstone
Trial Coordinator
x 26738
STUDIES OPEN TO RECRUITMENT
TRIAL No.
ON/4210
NeoSCOPE
Location of trial
treatment: CDU
and radiotherapy
STUDY
DESCRIPTION
Neoadjuvant - Study of
Chemoradiotherapy in
OesoPhagEal Cancer A randomised Phase II
study of two
preoperative
chemoradiotherapy
regimes (oxaliplatin
and capecitabine
followed by
radiotherapy with
either oxaliplatin and
capecitabine or
paclitaxel and
carboplatin) for
resectable
oesophageal cancer.
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
Angela Webb
Research Nurse
x 26753/bleep 2195
Sharon Short
Research Nurse
x 26751/bleep 3463
Dr S J Falk
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Velindre
NHS Trust
(NIHR)
16/09/2013
Emily Foulstone
Trial Coordinator
x 26738
Angela Webb
Research Nurse
x 26753/bleep 2195
ON/2013/4398
GO2
Alternative
chemotherapy for frail
or elderly patients with
advanced gastric or
oesophageal cancer
Sharon Short
Research Nurse
x 26751/bleep 3463
Dr S Falk
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Uni of
Leeds
(NIHR)
Open
18/03/2014
Emily Foulstone
Trial Coordinator
x 26738
UROLOGY
Stephen Lang
Research Nurse
x 26745/bleep 6225
ON/2475
STAMPEDE
Metastatic
Location of trial
treatment: CDU or
oral
Systemic Therapy in
Advancing or
Metastatic Prostate
Cancer; Evaluation of
Drug Efficacy
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Dr A Bahl
Sharon Short
Research Nurse
x 26751/bleep 3463
MRC
(NIHR)
29/10/2007
CRUK
(NIHR)
12/02/2007
Kimberly Rockley
Trial Coordinator
x 26748
ON/2411
RAPPER
Location of trial
treatment: N/A
Blood study
Radiogenomics:
Assessment of
polymorphisms for
predicting the effects
of radiotherapy
(Prostate)
Dr A Bahl
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
STUDIES OPEN TO RECRUITMENT
TRIAL No.
STUDY
DESCRIPTION
P.I.
Also open at NBT
Location of trial
treatment: LG2
Radiotherapy or
N/A for hormone
therapy
ON/3504
SORMET
(FLT-PET/CT)
Metastatic
Location of trial
treatment: N/A
Radiotherapy and
androgen deprivation
in combination after
local surgery: a
randomised controlled
trial in prostate cancer
SPONSOR/
PORTFOLIO
DATE
OPENED
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
ON/2703
RADICALS
adjuvant
CONTACT
Dr A Bahl
Dana Weston
Research
Radiographer
x 26754/bleep 2436
MRC
(NIHR)
24/07/2008
Investigator
led
25/02/2011
EORTC /
NIHR
14/03/2012
CRUK/NIHR
22/08/2012
Helen Saldanha
Trial Coordinator
x 26740
Prediction of clinical
benefit from sorafenib
in metastatic renal cell
cancer using FLTPET/CT
Dr J Kabala
Dr J Kabala
Seonaid Wright
Research Nurse
x 26755/bleep 2459
ON/3767
SURTIME
Location of trial
treatment: Oral
Randomised phase III
trial comparing
immediate versus
deferred nephrectomy
in patients with
synchronous
metastatic renal cell
carcinoma
Sharon Short
Research Nurse
x 26751/bleep 3463
Dr A Bahl
Stephen Lang
Research Nurse
x 26745/bleep 6225
Kimberly Rockley
Trial Coordinator
x 26748
ON/3902
PLUTO
Location of trial
treatment: CDU or
oral
A randomised phase II
study investigating
pazopanib vs weekly
paclitaxel in relapsed
or progressive
transitional cell
carcinoma (tcc) of the
urothelium (PLUTO):
A randomised phase ii
study investigating
pazopanib vs weekly
paclitax
Sharon Short
Research Nurse
x 26751/bleep 3463
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Dr A Bahl
Stephen Lang
Research Nurse
x 26745/bleep 6225
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
STUDIES OPEN TO RECRUITMENT
TRIAL No.
STUDY
DESCRIPTION
P.I.
CONTACT
PORTFOLIO
DATE
OPENED
Investigator
led
02/05/2012
University of
Birmingham
(NIHR)
15/11/2012
ICR (NIHR)
18/12/12
SPONSOR/
Seonaid Wright
Research Nurse
x 26755/bleep 2459
ON/3775
BRISTOL
BLADDER
TRIAL
Location of trial
treatment: Ward
61
Bristol Bladder trial: A
phase II trial of
combination
Cabazitaxel + Cisplatin
in the Neo-adjuvant
treatment of
transitional cell
carcinoma of the
Urinary bladder
Sharon Short
Research Nurse
x 26751/bleep 3463
Dr A Bahl
Stephen Lang
Research Nurse
x 26745/bleep 6225
Sylvia Pearson
Snr Trial Coordinator
x 26747
Sharon Short
Research Nurse
x 26751/bleep 3463
ON/4013
PAz02
Location of trial
treatment: Oral
A study of pazopanib
efficacy and safety in
patients with advanced
clear cell renal cell
carcinoma and ECOG
Performance Status 2
(PaZ02)
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Dr A Bahl
Stephen Lang
Research Nurse
x 26745/bleep 6225
Kimberly Rockley
Trial Coordinator
x 26748
Seonaid Wright
Research Nurse
x 26755/bleep 2459
ON/4056
POUT
Location of trial
treatment: Ward
61
A phase III randomised
trial of peri-operative
chemotherapy versus
surveillance in upper
tract urothelial cancer
Sharon Short
Research Nurse
x 26751/bleep 3463
Dr A Bahl
Stephen Lang
Research Nurse
x 26745/bleep 6225
Helen Boal
Clinical Trials Officer
x 26737/bleep 6342
STUDIES OPEN TO RECRUITMENT
TRIAL No.
STUDY
DESCRIPTION
P.I.
CONTACT
SPONSOR/
PORTFOLIO
DATE
OPENED
Sharon Short
Research Nurse
x 26751/bleep 3463
ON/4053
A-PREDICT
ON/4318
PROMPTS
ON/4262
PROSTVAC
A Phase II Study of
Axitinib in Patients with
Metastatic Renal Cell
Cancer Unsuitable
for Nephrectomy
A prospective
randomised phase III
study of observation vs
screening MRI and
pre-emptive treatment
in castrate resistant
prostate cancer
patients with spinal
metastases
A randomised, double
blind, phase III efficacy
trial of Prostvac V/F+/GM-CSF in men with
asymptomatic or
minimally symptomatic
metastatic, castrate
resistant prostate
cancer
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Dr A Bahl
Stephen Lang
Research Nurse
x 26745/bleep 6225
Commercial
(NIHR)
22/11/2013
Kimberly Rockley
Trial Coordinator
x 26748
Dorothy Griffiths
Research
Radiographer
x 26739/bleep 3013
Dr A Bahl
Dana Weston
Research
Radiographer
x 26754/bleep 2436
ICR (NIHR)
29/11/2013
Commercial
19/12/2013
The
University of
Glasgow and
NHS Greater
Glasgow and
Clyde
(NIHR)
11/03/2014
Kimberly Rockley
Trial Coordinator
x 26748
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Sharon Short
Research Nurse
x 26751/bleep 3463
Dr A Bahl
Stephen Lang
Research Nurse
x 26745/bleep 6225
Sylvia Pearson
Snr Trial Coordinator
x 26747
ON/3855
SAPROCAN
Saracatanib
(AZD0530) and
docetaxel in
metastatic, castrate
refractory prostate
cancer A phase
I/randomised phase II
study by the UK NCRI
prostate clinical
studies group.
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Sharon Short
Research Nurse
x 26751/bleep 3463
Dr A Bahl
Stephen Lang
Research Nurse
x 26745/bleep 6225
Kimberly Rockley
Trial Coordinator
x 26748
STUDIES OPEN TO RECRUITMENT
TRIAL No.
ON/4482
ZEBRA
STUDY
DESCRIPTION
An open label,
randomised, phase II
study comparing
AZD2014 versus
EVEROLIMUS in
patients with advanced
metastatic renal
cancer and
progression on VEGF
Targeted therapy
(NIHR)
P.I.
CONTACT
PORTFOLIO
DATE
OPENED
(NIHR)
27/03/2014
SPONSOR/
Seonaid Wright
Research Nurse
x 26755/bleep 2459
Sharon Short
Research Nurse
x 26751/bleep 3463
Dr A Bahl
Stephen Lang
Research Nurse
x 26745/bleep 6225
Kimberly Rockley
Trial Coordinator
x 26748
STUDIES IN SET-UP
TRIAL No.
STUDY TITLE
P.I.
SPONSOR/
PORTFOLIO
BMT
A Randomised Trial of the FLAMSA-BU CondItioning
ReGimen in Patients with Acute Myeloid Leukaemia
and Myelodysplasia UndeRgoing AllOgeneic Stem
Cell Transplantation
DM
Uni of B’ham
(NIHR)
A two part study to assess the tolerability, safety and
pharmacodynamics of Sativex in combination with
dose-intense Temozolomide in patients with
recurrent glioblastoma
KIH
Commercial
ON/2013/4234
CONCEPT
A randomised phase II pilot study of 3 weekly
Cabazitaxel versus weekly Paclitaxel chemotherapy
in the first line treatment of HER2 negative
metastatic breast cancer
AKB
BHOC/UHB led
study
ON/2014/4528
M14-011
A Randomised, Placebo-Controlled, Double-Blind,
Phase 3 Study Evaluating Safety and Efficacy of the
Addition of Veliparib Plus Carboplatin Versus the
Addition of Carboplatin to Standard Neoadjuvant
Chemotherapy Versus Standard Neoadjuvant
Chemotherapy in Subjects with Early Stage Triple
Negative Breast Cancer (TNBC)
CGP
Commercial
An International Multicentre Open Label
Randomised Phase II Advanced Anal Cancer Trial
Comparing Cisplatin plus 5-fluorouracil versus
Carboplatin plus Weekly Paclitaxel in Patients with
Inoperable Locally Recurrent or Metastatic Disease
SJF
NIHR
ON/2009/3167
WT1 TCR
Gene Therapy for Leukaemia: A Phase I/II Safety
and Toxicity Study (WT1 TCR-001).
SR
UCL (NIHR)
ON/2010/3573
FCLL
Currently on hold
Genetic study of chronic lymphocytic leukaemia and
other lymphoproliferative disease
RSE
ICR (NIHR)
DM
Commercial
RR
Commercial
PM
NIHR
ON/2013/4341
FIGARO
BRAIN
ON/2014/4521
SATIVEX
BREAST
COLORECTAL
ON/2014/4498
InterAACT
HAEMATOLOGY
A Phase 3, Randomized, Open Label Study
ON/2013/4413
TOWER
ON/2014/4533
GO28667
ON/2013/4465
AML18
Blinatumomab Versus Standard of Care
Chemotherapy in Adult Subjects With
Relapsed/Refractory B-precursor Acute
Lymphoblastic Leukemia (ALL)
A multicentre, phase iii, open-label, randomized
study in relapsed/refractory patients with chronic
lymphocytic leukaemia to evaluate the benefit of gdc0199 (abt-199) plus rituximab compared with
bendamustine plus rituximab
A trial for older patients with acute myeloid leukaemia
and high risk myelodysplastic syndrome
STUDIES IN SET-UP
TRIAL No.
STUDY TITLE
P.I.
SPONSOR/
PORTFOLIO
LUNG
ON/2013/4488
STOMP
ON/2014/4506
RESPECT-MESO
Currently on hold
Small cell lung cancer Trial of Olaparib (AZD2281)
as Maintenance Programme: a randomised, double
blind, multicentre phase II trial
A multi-centre non-blinded randomised controlled
trial to assess the impact of regular early specialist
symptom control treatment on quality of life in
malignant mesothelioma
AD
NIHR
PCW
Commercial
SJF
Commercial
SJF
Cambridge
University
Hospitals NHS
Trust (NIHR)
UPPER GI
ON/2013/4435
COAST – BAY 73-4506 15983
ON/2013/4429
SIEGE
A Randomized, Double-blind, Placebo-controlled
Phase-III Study of Adjuvant Regorafenib Versus
Placebo for Patients with Stage IV Colorectal Cancer
After Curative Treatment of Liver Metastases
(Scheduling nab-paclitaxel with gemcitabine):
Randomised phase II trial to investigate two different
schedules of nab-paclitaxel (Abraxane) combined
with gemcitabine as first line treatment for metastatic
pancreatic ductal adenocarcinoma
UROLOGY
ON/2013/4233
JAVA-P
A Phase II Trial of Cabazitaxel Chemotherapy in
Relapsed Locally Advanced & metastatic Carcinoma
of the Penis
AKB
BHOC/UHB led
study
ON/2014/4559
PROSPER
A Multinational, Phase 3, Randomized, Double-Blind,
Placebo-Controlled, Efficacy and Safety Study of
Enzalutamide in Patients With non metastatic
Castration-Resistant Prostate Cancer
AKB
Commercial